Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01986777
Other study ID # 817628
Secondary ID
Status Withdrawn
Phase N/A
First received October 30, 2013
Last updated September 15, 2017
Start date July 2013
Est. completion date December 2013

Study information

Verified date September 2017
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a double-blind, placebo-controlled, study testing whether LDX improves cognitive function and EF in 20 postmenopausal women who report onset of cognitive difficulties after oophorectomy (with or without subsequent chemo/adjunctive therapy). Brain imaging is included at critical time points to obtain objective data regarding effects of LDX as well as potential predictors of resilience in the face of oophorectomy.


Description:

Participants will be asked to undergo three brain-imaging scans throughout the course of the study. Once they are deemed eligible for participation based on two assessment visits, they will be scheduled for their baseline test day. On this they, they will be asked to under a series of cognitive tests following by a brain-imaging scan. They will then take the first dose of either the LDX or placebo, wait for 3 hours and then undergo another brain-imaging scan to assess acute changes to memory/cognition due to the study drug. They will then come in for three 30-minute check-in visits during weeks 2, 4 and 6 on the study drug. They will be asked to undergo a final scan and series of cognitive tasks during weeks 8-10 on the study drug. They will then be discharged from active study participation. All participants, regardless of randomization, will be offered a consultation with the study MD and optional prescription for 4-weeks of treatment with LDX.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria:

- Female;

- Age 30-60;

- Have undergone surgically-induced menopause by oophorectomy or chemically-induced menopause within the previous 10 years;

- Have at least moderate executive functioning difficulties as evidenced by a score of 25 on the BADDS;

- Have no history of a DSM-IV psychiatric disorder within the previous year or substance dependence disorder within the previous 5 years (psychostimulant abuse lifetime history), according to the Structured Clinical Interview for Diagnosis-DSM-IV (SCID)-Non-Patient Version;

- Subject has history of substance abuse disorders (this includes alcohol, prescription, and illicit substances) 3 years ago but the period of abuse did not last more than 5 years according to the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-NP);

- Are able to give written informed consent (obtained at screening visit);

- Must have clear urine toxicology screen upon recruitment;

- Are fluent in written and spoken English;

- Are right-handed.

Exclusion Criteria:

- Mini-mental status exam score of 24;

- Presence of a psychiatric disorder within previous year or a life time history of ADHD or psychotic disorder including bipolar disorder, schizoaffective disorder and schizophrenia;

- Lifetime history of drug addiction or abuse, except nicotine; 4. Regular use of psychotropic medication except for a selective serotonin reuptake inhibitor or serotonin/norepinephrine reuptake inhibitor or standard sleep medication at a stable dose for at least one month prior to enrollment;

- Regular use (more than once a week) of alcohol that is 3 drinks/day;

- Presence of a contraindication to treatment with stimulant medication; this would include the presence of controlled or uncontrolled hypertension, coronary disease, atrial fibrillation, and arrhythmia;

- History of seizures;

- History of cardiac disease including known cardiac defect or conduction abnormality;

- Abnormal electrocardiogram during screening;

- Presence of a metallic implant;

- Claustrophobia.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
lisdexamfetamine

Placebo
The placebo capsules will be filled with lactose.

Locations

Country Name City State
United States Penn Center for Women's Behavioral Wellness Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary BADDS Score To determine whether treatment with LDX improves self-reported executive function (EF) as measured with the BADDS 8-10 weeks
Secondary Brain Activation To determine the impact of LDX on brain activation in the brain during a working memory task. 8-10 weeks
See also
  Status Clinical Trial Phase
Completed NCT04470219 - Digital Support for People With Cognitive Impairment N/A
Completed NCT01071044 - Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome Phase 4
Completed NCT02962687 - Video-Enhanced Care Management for Medically Complex Veterans N/A
Completed NCT01324024 - Attention & Memory Impairments in Menopausal Women Phase 4
Recruiting NCT05053204 - Influence Factors and Cognitive Characteristics in Unipolar and Bipolar Depression:Based on the THINC-it Tool
Recruiting NCT02778581 - Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment N/A
Suspended NCT00197483 - Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia Phase 2
Completed NCT05585424 - Effectiveness of a Program Based on Observation-action Training (AOT) in Patients With Cognitive Impairment. N/A
Completed NCT05822596 - Tablet-based Interactive Games in Elderly With Cognitive Impairment and Persons With Intellectual Disability N/A
Completed NCT02830854 - Molecular Hydrogen for Cognitive Function and Performance in Elderly Phase 3
Recruiting NCT01466205 - Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder Phase 2
Recruiting NCT05896189 - Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors N/A
Not yet recruiting NCT06212726 - RTL Concussion Communication N/A
Completed NCT02868684 - Imaging Biomarkers of Mild Traumatic Brain Injury: a Longitudinal Cohort Study
Recruiting NCT04490330 - Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients
Completed NCT02677987 - The "Light for the Brain" Study N/A
Completed NCT02746484 - ABILITY - TelerehABILITation: TechnologY-enhanced Multi-domain at Home Continuum of Care Program N/A

External Links